|
1
|
Vallée A, Lelong H, Lopez-Sublet M, Topouchian J, Safar ME, Blacher J. Reply. J Hypertens 2019; 37:2499-2500. [PMID: 31688294 DOI: 10.1097/hjh.0000000000002215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Alexandre Vallée
- Hypertension and Cardiovascular Prevention Unit, Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, AP-HP, Paris-Descartes University
| | - Hélène Lelong
- Hypertension and Cardiovascular Prevention Unit, Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, AP-HP, Paris-Descartes University
| | - Marilucy Lopez-Sublet
- Department of Internal Medicine, AP-HP Hôpital Avicenne, European Society of Hypertension Excellence Center, Paris, France
| | - Jirar Topouchian
- Hypertension and Cardiovascular Prevention Unit, Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, AP-HP, Paris-Descartes University
| | - Michel E Safar
- Hypertension and Cardiovascular Prevention Unit, Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, AP-HP, Paris-Descartes University
| | - Jacques Blacher
- Hypertension and Cardiovascular Prevention Unit, Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, AP-HP, Paris-Descartes University
| |
Collapse
|